Find policies, billing codes, payers, states, and providers
Omalizumab products (Xolair, Omlyclo) coverage
Customize your policy alerts
Sign up for Premera Bluecross Policy 5.01.513 alerts
Get alerted when Policy 5.01.513 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity, site-of-service review, and coverage criteria for omalizumab products (Xolair and Omlyclo) across indications including moderate-to-severe persistent asthma, chronic idiopathic urticaria, chronic rhinosinusitis with nasal polyps (CRSwNP), and IgE-mediated food allergy; applies to providers submitting medical or pharmacy benefit requests.
Updated initial authorization for all reviews from 6 months to 12 months.
Added Exdensur (depemokimab-ulaa) to the list of medications not to be used concurrently with omalizumab for the treatment of asthma.
Updated chronic idiopathic urticaria (CIU) dose limit to 600 mg every 2 weeks.
Updated asthma coverage criteria to use maximum tolerated doses of an inhaled corticosteroid instead of maximum doses.
Removed requirement that adults be non-smokers or enrolled in a smoking cessation program for asthma indication.
Included treatment of certain individuals with IgE-mediated food allergies in the coverage criteria.
Policy title updated from Xolair (omalizumab) to Omalizumab Products and Omlyclo (omalizumab-igec) was added with the same criteria as Xolair.
Updated chronic rhinosinusitis with nasal polyps (CRSwNP) criteria to clarify diagnostic requirements and prior systemic corticosteroid or prior surgery requirements.
Updated chronic idiopathic urticaria criteria to remove prior combination therapy requirement and added restrictions on concurrent use with Dupixent and remibrutinib (Rhapsido).
Asthma criteria updated to remove the adult non-smoker requirement and to add additional exacerbation-based diagnostic options and FEV1/FVC < 0.80 as an option.
Coverage Criteria and Indication-Specific Requirements
Moderate to severe persistent asthma (site-of-service criteria noted)
Covered when ALL of the following are met
ALL of the following
- age: The individual is aged 6 years or olderage >=6
- controller therapy: Using maximum tolerated doses of an inhaled corticosteroid
Policy updated to require maximum tolerated dose rather than absolute maximum dose (2025 update).
- LABA: Using an inhaled long-acting beta-agonist (LABA)
Meets ONE of
- Two or more asthma exacerbations in the previous 12 months requiring use of oral corticosteroids
- One or more asthma exacerbations requiring hospitalization, emergency department, or urgent care visit in the previous 12 months
- Forced expiratory volume in 1 second (FEV1) < 80% predictedFEV1 <80% predicted
- FEV1/forced vital capacity (FVC) < 0.80FEV1/FVC <0.80
- Asthma that worsens upon tapering of oral corticosteroid therapy (dependence or inability to taper)
- IgE level: Total serum IgE 30–1,300 IU/mL for ages 6–12 OR 30–700 IU/mL for ages ≥12
Used with body weight to determine asthma dosing per dosing tables.
- allergen test: Positive skin test or RAST (serum specific IgE) to a perennial aeroallergen (e.g., dust mite, cockroach, dog, cat, molds)
- weight: Weight between 20 kg and 150 kg20-150 kg
- dosing limit: Dose limited to 750 mg every 4 weeks based on serum IgE and body weight dosing table
- concomitant therapy exclusion: Not used in combination with specified biologics when used for treatment of asthma (Cinqair/reslizumab, Dupixent/dupilumab, Exdensur/depemokimab-ulaa, Fasenra/benralizumab, Nucala/mepolizumab, Tezspire/tezepelumab)
List expanded in policy updates; concurrent use may trigger denial.
- prescriber: Prescribed by or in consultation with an allergist, immunologist, or pulmonologist
ALL of the following
- site-of-service review: Site-of-service administration review applies per policy (applies to injection drugs and affects where administration is considered medically necessary)
Added in 2025; see site-of-service criteria for denial triggers.
ALL of the following
- authorization length: Prior authorization is required; initial authorization may be approved up to 12 months when medical necessity criteria are met and clinical response is documented12 months
Initial authorization length updated from 6 to 12 months (2026 update).
Severe chronic idiopathic urticaria
Covered when ALL of the following are met
ALL of the following
- age: The individual is aged 12 years or olderage >=12
- exclude other causes: No evidence of another cause of the urticarial reaction
- duration: At least 6 weeks of symptoms (chronic urticaria, itching, hives, or angioedema)
- antihistamine failure: Failed or intolerant to at least 2 H1-antihistamines at high doses (at least twice normal dosing and up to 4x normal dosing) or maximum tolerated dose
Policy requires step therapy before omalizumab for CIU.
- concomitant antihistamine: Plans to continue treatment with a low dose of H1 antihistamines during omalizumab therapy
- combination exclusion: Medication will not be used in combination with Dupixent (dupilumab) or Rhapsido (remibrutinib) for chronic urticaria
Concurrent use restricted per 2025/2026 updates.
- dose limit: Dose limited to 600 mg every 2 weeks
CIU dose limit added/clarified in 2026 update; 75 mg dose did not demonstrate consistent efficacy and is not approved.
- prescriber: Prescribed by or in consultation with an allergist, immunologist, or pulmonologist (or dermatologist as appropriate)
Chronic rhinosinusitis with nasal polyps (CRSwNP)
Covered when ALL of the following are met
ALL of the following
- age: The individual is aged 18 years or olderage >=18
- symptom criteria: Has at least 2 of: facial pressure or pain; moderate–severe nasal congestion, discharge, or obstruction; significant loss of smell
- IgE: Pretreatment total serum IgE at least 30 IU/mL
Used with body weight to determine dosing when applicable.
- weight: Weight between 30 kg and 150 kg30-150 kg
- diagnosis confirmation: Inadequately controlled bilateral CRSwNP confirmed by physical exam, sinus CT, or nasal endoscopy
- intranasal steroid trial: Tried and had inadequate response or intolerance to intranasal corticosteroid monotherapy
- combination: Medication prescribed in combination with an intranasal corticosteroid
Background nasal mometasone required in trials.
One of
- Prior systemic corticosteroid use to treat nasal polyps in the last 2 years
- Contraindication to systemic corticosteroid therapy
- Previous surgical removal of bilateral nasal polyps (bilateral polypectomy)
- dose limit: Dose limited to 600 mg every 2 weeks based on serum IgE and body weight dosing table
- combination exclusion: Medication will not be used in combination with Dupixent (dupilumab), Nucala (mepolizumab), or Tezspire (tezepelumab) for CRSwNP
Concurrent use restricted per updates.
- prescriber: Prescribed by or in consultation with an allergist, immunologist, or otolaryngologist (ENT)
IgE-mediated food allergy
Covered when ALL of the following are met
ALL of the following
- age: The individual is aged 1 year or olderage >=1
- diagnosis: Diagnosis demonstrated by ALL: signs/symptoms of a significant systemic allergic reaction shortly after known ingestion of one or more foods AND a positive skin prick test OR positive serum specific IgE to one or more foods
- concomitant therapy: Medication will be used in conjunction with a diet that avoids the food allergens
- combination exclusion: Medication will not be used concomitantly with Palforzia (peanut allergen powder)
- epinephrine: Individual has been prescribed an epinephrine auto-injector
- dose limit: Dose limited to 600 mg every 2 weeks based on serum IgE and body weight dosing table
Dose cap aligns with prescribing information and 2026 policy updates.
- prescriber: Prescribed by or in consultation with an allergist, immunologist, or otolaryngologist (ENT)
Investigational/Not covered indications
ALL of the following
- investigational list: Omalizumab products are considered investigational for other uses not listed including allergic rhinitis, atopic dermatitis, other IgE-mediated allergic conditions not listed, latex allergy, bullous pemphigoid
Policy lists these conditions as investigational/uncovered.
Maintenance Therapy of Asthma (general coverage basis)
Covered when ALL of the following are met (as supported by rationale and trial inclusion):
ALL of the following
- population: Individual has moderate to severe persistent asthma inadequately controlled despite optimized standard therapy (inhaled corticosteroid plus usually a LABA and other controllers as clinically indicated)
Policy and rationale support use as add-on therapy in inadequately controlled individuals.
- individualized treatment: Treatment is individualized consistent with guidelines and trial populations
- supporting evidence: Pivotal trials demonstrated reduction in exacerbations and healthcare utilization in individuals inadequately controlled on standard therapies
Chronic Idiopathic Urticaria (CIU)
Covered for Chronic Idiopathic Urticaria when ALL of the following trial-like criteria are present:
ALL of the following
- UAS7: Weekly Urticaria Activity Score (UAS7) ≥16UAS7 >=16
Per CIU pivotal trials entry requirement.
- itch severity: Weekly itch severity score ≥8 for the 7 days prior to treatment initiationweekly itch >=8
Per CIU trials; demonstrates severe disease despite antihistamine use.
- antihistamine background: Symptoms persist despite use of an H1 antihistamine at an approved dose for at least 2 weeks
Required run-in condition in CIU trials.
- efficacious doses: Clinical trial efficacy demonstrated for 150 mg and 300 mg doses; 75 mg did not demonstrate consistent efficacy
Policy excludes 75 mg as effective dose.
Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Covered for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) when ALL of the following trial-like criteria are present:
ALL of the following
- NPS and NCS: Endoscopic nasal polyp score (NPS) total ≥5 with NPS ≥2 in each nostril AND weekly average nasal congestion score (NCS) >1 despite use of nasal mometasone during run-inNPS >=5 with >=2 per nostril; mean NCS >1
Matches entry criteria used in pivotal CRSwNP trials.
- background nasal steroid: Required background nasal mometasone during run-in and treatment periods
Trials required background intranasal steroid use.
- diagnosis confirmation: Bilateral CRSwNP confirmed by physical exam, sinus CT, or nasal endoscopy
IgE-Mediated Food Allergies
Covered for IgE-mediated Food Allergies in contexts matching trial populations when ALL are present:
ALL of the following
- trial population: Individuals allergic to peanut and at least two other foods studied in the OUtMATCH trial and treated per the trial design to facilitate food challenge tolerance
Efficacy evidence derives from the NIAID-sponsored OUtMATCH randomized trial (pediatric-dominant population).
- use context: Medication used to reduce Type I allergic reactions and facilitate oral food challenge/tolerance protocols in conjunction with avoidance diet and clinical monitoring
Open-label extension provided limited longer-term data; adult effectiveness supported by extrapolation from pediatric data.
Coverage-related policy updates and indication constraints
Policy updates and indication-specific requirements noted in the rationale and update history
List of prohibited concurrent biologics expanded in 2024 and 2026 updates.
Updated from 6 months in 2026 update.
Added/clarified in 2026 update.
Diagnostic options updated in 2024–2025 updates.
Clarified in 2025 updates.
Dosing-based coverage for asthma and CIU
Covered when dosing and documentation meet indication-specific requirements
Do not use IgE measured during ongoing therapy for dose determination; if treatment interrupted <1 year use baseline IgE; if interrupted ≥1 year re-test total serum IgE; adjust doses for significant body weight changes.
Duration not definitively evaluated; periodically reassess need for continued therapy and document chosen dose and rationale.
Chronic Idiopathic Urticaria (CIU)
Coverage applies when individuals meet the indication-specific criteria and prior therapy/diagnostic requirements described in policy.
ALL of the following
- CIU dosing: Administer Xolair 150 mg or 300 mg subcutaneously every 4 weeks; dosing is not dependent on serum IgE or body weightevery 4 weeks
Document dosing chosen (150 vs 300 mg) and rationale; prior authorization updated to 12 months.
- prior antihistamine trials: Document failure or intolerance to at least 2 H1 antihistamines at high doses or maximum tolerated dose prior to initiation
Per CIU step therapy requirement.
IgE-based Dosing Guidance
Dose determination rules for asthma and other indications where IgE-based dosing applies:
ALL of the following
- IgE testing and timing: Total serum IgE levels are elevated during treatment and remain elevated for up to one year after discontinuation; re-testing during treatment cannot be used for dose determination1 year
If treatment interrupted <1 year use the original baseline IgE for dosing; if interrupted ≥1 year re-test total serum IgE for dosing.
- weight changes: Adjust doses for significant changes in body weight according to dosing tables
Moderate to Severe Persistent Asthma
Asthma and other indication eligibility updates (summary of recent criteria changes):
Policy removed adult non-smoker requirement (2024) and updated ICS criterion to maximum tolerated dose (2025).
Omalizumab products (Xolair and Omlyclo) are considered investigational for uses not specifically listed as covered in this policy. Examples of investigational or not-covered indications include allergic rhinitis, atopic dermatitis, other IgE-mediated allergic conditions not listed, latex allergy, and bullous pemphigoid. Requests for these indications should be denied as not medically necessary per the policy's investigational exclusions.
Clinical trial evidence for chronic idiopathic urticaria (CIU) showed benefit for the 150 mg and 300 mg subcutaneous doses administered every 4 weeks; the 75 mg dose did not demonstrate consistent efficacy in the randomized trials and is not an approved dose for CIU.
The policy prohibits concurrent use of omalizumab with certain other biologic therapies for asthma or nasal polyps. Over successive updates the list of excluded biologics has expanded and now includes agents such as tezepelumab, dupilumab, and the recently added Exdensur (depemokimab-ulaa). Requests for concurrent administration for the same indication may be denied.
Total serum IgE values rise during omalizumab treatment and may remain elevated for up to one year after discontinuation. Therefore, do not determine or adjust omalizumab dose using total serum IgE levels measured during ongoing treatment; such in-treatment IgE testing is not a valid basis for dosing decisions.
Concurrent use of omalizumab with other listed biologics (for example Dupixent/dupilumab, Tezspire/tezepelumab, Cinqair/reslizumab, Fasenra/benralizumab, Nucala/mepolizumab, and newly added agents such as Exdensur/depemokimab-ulaa, or investigational agents like remibrutinib) for the same indication is restricted by this policy and may render the request not medically necessary.
Site-of-service review applies to administration of omalizumab products. When the policy's site-of-service criteria are not met, hospital-based outpatient settings or other higher-cost sites for infusion and injectable therapy services are considered not medically necessary. Preferred medically necessary sites include the physician's office, infusion centers, and home infusion when those criteria are satisfied.
Use of omalizumab is supported only for individuals who meet the indication-specific, trial-like entry criteria and who remain inadequately controlled despite optimized standard therapies. For asthma, prior documentation should show inadequate control on appropriate controller regimens (e.g., inhaled corticosteroids plus other controllers) and meet the policy's exacerbation or lung function thresholds; use outside these trial-like contexts is not supported.
The policy sets a maximum CIU dosing limit that must be followed: requests that exceed a total dose of 600 mg every 2 weeks are not supported by this update and may be denied.
The dosing tables include explicit DO NOT DOSE entries for certain very high pre-treatment total serum IgE and weight combinations (for example, specific bands >900 IU/mL with certain weight ranges). These combinations are considered ineligible per the dosing table and should not be dosed.
Re-testing total serum IgE during ongoing omalizumab treatment is not acceptable for dose determination because total IgE remains elevated during treatment and for up to one year after discontinuation. If treatment is interrupted for less than 1 year, the original baseline IgE used for initial dosing should be used; only after an interruption of 1 year or more should total serum IgE be re-measured to guide dose selection.
Coding, Dose Limits, and Key Numeric Parameters
| NDCs referenced in prescribing information | See Xolair and Omlyclo prescribing information listed in references for product-specific NDCs and formulations. |
| J2357 | Injection, omalizumab, 5 mg |
Prior Authorization, Documentation, and Operational Requirements
Prior authorization required; approvals up to 12 months
Prior authorization is required for omalizumab product requests; initial and reauthorization approvals may be granted up to 12 months when medical necessity criteria are met and clinical response is documented.
- Reauthorization for asthma, CIU, CRSwNP, and IgE‑mediated food allergy may be approved up to 12 months if medical necessity and positive clinical response are documented (e.g., reduced steroid use, fewer exacerbations, improved symptoms or quality of life).
Confirm inadequate control on standard therapy
Prior authorization must document inadequate control despite standard controller therapies (for asthma, e.g., use of maximum tolerated inhaled corticosteroid plus long‑acting beta‑agonist and other controllers) before omalizumab is authorized.
- Confirm trials of optimized inhaled corticosteroid therapy (maximum tolerated dose) and usually a LABA, plus other controllers as appropriate.
Prior authorization with 12‑month initial approval
Prior authorization requests must reference that initial approval length is 12 months for all reviews as specified in the policy.
- The 2026 update set initial authorization for all reviews to 12 months and removed prior references to non‑formulary exception review durations.
Reference dosing table (IgE + weight) on PA requests
Prior authorization requests for asthma (and other IgE‑based indications) must reference the appropriate omalizumab dosing table using pre‑treatment total serum IgE and body weight; CIU requests should reference fixed 150 mg or 300 mg q4w dosing tables where applicable.
- For asthma: include pre‑treatment total serum IgE (IU/mL) and current body weight to select mg dose and 2‑ or 4‑week administration frequency from the dosing tables.
- For CIU: document selection of 150 mg or 300 mg SC every 4 weeks per dosing guidance.
Initial authorization period updated to 12 months
Initial prior authorization period for omalizumab product reviews has been updated to 12 months for all reviews per the 2026 policy update.
- This change applies to all omalizumab product authorizations effective in the 2026 update.
CIU step therapy: failed ≥2 high‑dose H1 antihistamines
For chronic idiopathic urticaria, prior authorization requires documentation of failure or intolerance to at least two high‑dose H1‑antihistamines (up to 4× normal dosing or maximum tolerated dose) before starting omalizumab.
- Policy expects continuation of a low‑dose H1 antihistamine during omalizumab therapy.
Policy supports omalizumab as add‑on for uncontrolled disease
Policy language supports using omalizumab as an additional option for individuals not controlled with inhaled corticosteroids and other controller therapy when criteria are met.
- Omalizumab is considered an add‑on after optimization of standard asthma controller regimens.
Document required prior therapies per indication
Prior authorization must document prior trials of standard therapies where specified by indication (e.g., CIU refractory to high‑dose H1 antihistamines; CRSwNP with prior systemic corticosteroid use or prior bilateral polypectomy or contraindication).
- For CRSwNP: document prior systemic corticosteroid use within 2 years, contraindication to systemic corticosteroids, or prior bilateral nasal polyp surgery per criteria.
Document background controller therapy trials
Provider should recognize omalizumab is add‑on therapy to standard asthma controller medications; the appendix lists inhaled corticosteroids, long‑acting bronchodilators, leukotriene modifiers, and oral corticosteroids as background controller options.
- Include history of use/intolerance of listed controller agents when submitting PA for asthma.
Indication‑specific prior therapy requirements
For CRSwNP and CIU, prior use of specific therapies or documented inadequate response may be required (e.g., prior systemic corticosteroids or prior sinus surgery for CRSwNP; for CIU prior high‑dose antihistamine steps).
- CRSwNP: document diagnosis of inadequately controlled bilateral disease and prior systemic steroid use in last 2 years or prior bilateral polypectomy or contraindication to systemic steroids.
- CIU: document failure/intolerance of ≥2 H1 antihistamines at high doses.
Required medical record documentation
Medical records submitted for review must document that medical necessity criteria are met and include office visit notes with diagnosis, relevant history, physical exam, and medication history.
- Include chart notes that demonstrate baseline disease status and subsequent clinical response for reauthorization.
Document trial‑like entry criteria (NPS, UAS7)
Document disease‑specific entry criteria used in clinical trials when applicable — for CRSwNP include endoscopic nasal polyp score (NPS) total ≥5 with ≥2 in each nostril and mean nasal congestion score >1 despite nasal mometasone; for CIU document UAS7 ≥16 and weekly itch ≥8 despite antihistamine therapy.
- Attach endoscopy or scoring documentation and symptom scores from the run‑in period where available.
Document dosing per FDA prescribing information
Document that dosing and administration follow the product's FDA prescribing information and record prior use/trials of therapies required by specific indication criteria.
- Include reference to the prescribing information dosing tables when indicating dose selection.
Document dosing choice and re‑testing after interruption ≥1 year
Document the dosing chosen and rationale (e.g., 150 mg vs 300 mg for CIU); if treatment was interrupted ≥1 year, include repeat total serum IgE testing for asthma dose determination.
- For interruptions <1 year, state rationale to use original pre‑treatment IgE for dose determination; for ≥1 year, provide new serum IgE result.
Required documentation of dosing regimen and IgE when interrupted
For dosing after treatment interruptions under 1 year, document the original pre‑treatment total serum IgE used to determine dose; for interruptions of one year or more, provide repeat total serum IgE for dose determination.
- Also document any significant weight change that would alter dose selection from the dosing tables.
Site‑of‑service denial triggers and SOS rules
Site‑of‑service requests may be denied if site‑of‑service criteria are not met (preferred outpatient sites, first‑90‑days rule, availability within 50 miles, contracted home infusion, or clinical risk criteria); hospital‑based outpatient infusion considered not medically necessary when criteria are unmet.
- Hospital outpatient setting is medically necessary for the first 90 days for initial course or re‑initiation after ≥6 months only when criteria are met.
- If no outpatient infusion center within 50 miles and no contracted home infusion, hospital setting may be considered medically necessary.
Denial risk if inadequate control on maximal therapy not shown
Lack of documented inadequate control on maximal/optimized therapy for asthma may undermine PA justification; pivotal trials showed benefit primarily in individuals inadequately controlled despite inhaled corticosteroids and other controllers.
- Ensure documentation of exacerbation history, FEV1/FEV1‑FVC data, steroid dependence, or other listed severity markers to support need for omalizumab.
Denial triggers: dose limits and prohibited concurrent biologics
Requests exceeding the chronic idiopathic urticaria dose limit (600 mg every 2 weeks) or requests for concurrent use with listed biologics (including newly added Exdensur/depemokimab‑ulaa) may be denied.
- Policy explicitly limits CIU dosing to 600 mg q2w; concurrent use with specified biologics for asthma/nasal polyps is prohibited.
IgE testing timing: do not use in‑treatment IgE for dosing
Do not use serum total IgE levels obtained during ongoing omalizumab treatment for dose determination because total IgE is elevated during and up to one year after treatment.
- If dose determination requires IgE and treatment was interrupted <1 year, use the original pre‑treatment IgE; re‑test only if interruption ≥1 year.
Combination therapy restrictions: no concurrent biologics
Concurrent use of omalizumab with listed biologics (e.g., Tezspire, Dupixent, Exdensur, remibrutinib and others identified in policy) for the same indication is restricted and can trigger denial.
- When submitting PA, state that omalizumab will not be used concurrently with the named biologic therapies for the same condition.
IgE re‑testing limitation for dose determination
Re‑testing total serum IgE during ongoing Xolair treatment is not acceptable for dose determination unless treatment was interrupted for one year or longer; using in‑treatment IgE to set dose may lead to denial.
- Document the timing of any treatment interruption and provide either original baseline IgE (if <1 year) or a new IgE (if ≥1 year) per dosing guidance.
Background, Mechanism, and Evidence Summary
Omalizumab (Xolair and biosimilar Omlyclo) is a recombinant, humanized anti-IgE monoclonal antibody indicated as add-on therapy in patients with severe allergic asthma not controlled on inhaled corticosteroids and other controllers, for chronic spontaneous urticaria refractory to antihistamines, for inadequately controlled chronic rhinosinusitis with nasal polyps, and to reduce Type I allergic reactions in certain IgE-mediated food allergy contexts. Its pharmacodynamic effect includes a rapid reduction in free IgE (approximately ≥96% reduction with recommended dosing) and total IgE increases due to complex formation; total IgE may remain elevated for up to one year after treatment discontinuation.
Definitions and Key Terms
Policy Updates and Material Changes
Initial authorization period for all omalizumab product reviews updated from 6 months to 12 months; reference to non-formulary exception reviews removed.
Chronic idiopathic urticaria (CIU) dose limit added/updated to 600 mg every 2 weeks.
Exdensur (depemokimab-ulaa) added to the list of biologics not to be used concurrently with omalizumab for asthma.
Clarified asthma criteria (use of maximum tolerated inhaled corticosteroid doses, addition of FEV1/FVC <0.80 option) and added site-of-service review and CRSwNP prior-treatment requirements.
Removed adult non-smoker requirement for asthma indication and added coverage of certain individuals with IgE-mediated food allergies (effective January 3, 2025 for those updates).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.